- Global Pharma News & Resources

Intraocular Melanoma Treatment Market Size 2020, Global Industry Overview, Growth, Trends, Top Companies, Share, Demand, Insight, and Regional Forecast to 2026

SEATTLE, April 02, 2021, (PHARMIWEB) — Intraocular (uveal) melanoma is a rare eye cancer, in which tumor cells are formed in the tissues of the eye. It is typically characterized with blurred vision or a dark spot on the iris. It begins in the middle of three layers of the wall of the eye. According to the National Cancer Institute (NCI), the standard treatments include surgery, radiation therapy, photocoagulation, and thermotherapy. There are some other treatments available that are being tested in clinical trials. For instance, Nivolumab: an immunotherapy drugs shown to help people suffering from uveal melanoma by increasing patient’s overall immunity, are presently in Phase II clinical study. Moreover, other similar drugs are being studied for uveal melanoma, which include combination of Ipilimumab and Nivolumab, and Selumetinib. In this, Selumetinib is a targeted drug known to slow down growth of eye melanoma, while nivolumab in combination with lpilimumab are being studied to control uveal melanoma as they are in Phase II clinical study.

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report@

Moreover, according to American Society of Clinical Oncology (ASCO), individuals belonging to Caucasian race, people with light eye color and fair skin, or any individual and any of their family member having history of suffering from dysplastic nevus syndrome are likely to develop intraocular melanoma. Moreover, over-exposure to sunlight and other risk factors of skin melanoma are some of the major causes of intraocular melanoma. Thus, these factors are expected to boost growth of the global intraocular melanoma treatment market during the forecast period.

Market Dynamics- Drivers

Increasing development of innovative treatment options in intraocular melanoma treatment are expected to drive growth of the global intraocular melanoma market during the forecast period. Various advancements in the treatment have been observed such as understanding the molecular characteristics of intraocular tumor through genetic alternations and mutations studies in patients and novel therapies based on inhibition mechanism of expression of growth factor receptors such as c-Met and c-Kit, are being investigated to bring better treatment options for patients.

Moreover, rapid research and development activities associated with melanoma coupled with increasing burden of intraocular melanoma, and increasing number of clinical trials for new treatments, are expected to drive growth of the global intraocular melanoma treatment market in the near future. For instance, according to the American Society of Clinical Oncology (ASCO), in 2015, around 3,540 adults (2,130 men and 1,410 women) in the U.S. were diagnosed with primary intraocular cancer. According to the American Academy of Ophthalmology (AAO), in 2014, uveal melanoma is the most commonly diagnosed primary intraocular malignancy in adults, with 90% of uveal melanoma involving the choroid, 5% affecting the ciliary body, and 5% developing in the iris. According to the same source, uveal melanoma accounts for 5%-10% of all melanomas. Furthermore, according to the American Academy of Ophthalmology (AAO), 2014 data findings, incidence of intraocular melanoma is higher among the fairly pigmented groups, while extremely lower among Asian and African population.

Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @

Key players in the market are focused on various strategies such as research and development to synthesize effective intraocular melanoma treatments. For instance, in June 2018, Aura Biosciences, a biotechnology company engaged in developing therapies to target and selectively destroy cancer cells using viral capsid conjugates, announced a new interim safety and efficacy data from an open-label Phase 1b/2 study, of AU-011; for the treatment of primary choroidal melanoma. Choroidal melanoma is the most common primary ocular tumor, which is commonly developed in the uveal tract of the eye.

Moreover, in May 2018, Immunocore Limited released its phase I/II dose escalation trial of IMCgp100, for metastatic uveal melanoma (mUM) treatment, which was presented at American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 4, 2018. Furthermore, patients suffering from metastatic uveal melanoma (mUM) treated with IMCgp100 continued to experience effective treatment response.

Market Dynamics- Restraints

Side effects associated with the treatment of intraocular melanoma and high cost require for its treatment along with poor reimbursement infrastructure are expected to hinder the global intraocular melanoma market growth during the forecast period.

Market Dynamics- Regional Insights

Among regions, in 2017, North America accounted for the major market share and is expected to show lucrative growth opportunities during the forecast period. This is owing to increasing initiatives by various government and private organizations in developing effective treatment options and growing incidence of intraocular melanoma in the region. For instance, according to the National Cancer Institute (NCI) data, in 2016, the mean age-adjusted incidence of uveal melanoma in the U.S. is around 4.3-8.4 new cases per million people per year.

Several research organizations, in the regions are focused on raising funding for research to develop intraocular melanoma treatment options. For instance, Melanoma Research Foundation (MRF), a Washington-based organization committed to develop effective treatment in various types of melanoma, raised around US$ 1.2 million for ocular melanoma and its treatment, since 2012. Furthermore, in April 2018, the Ocular Melanoma Foundation (OMF), in collaboration with the American Association for Cancer Research (AACR), offered research funding of US$ 150,000 to researchers at the Casey Eye Institute, to study circulating hybrid tumor cells as a prognostic biomarker for ocular melanoma.

To understand Research Methodology, please click

Competitive Landscape

Key companies operating in the global intraocular melanoma market are Astra Zeneca plc, Eli Lilly & Co., Pfizer, Inc. Novartis AG, and Spectrum Pharmaceuticals, Inc.

Global Intraocular Melanoma Treatment Market Taxonomy

By Treatment

  • Targeted Therapy
    • Rituximab (Rituxan)
    • Ibritumomab (Zevalin)
    • Imatinib (Gleevec)
    • Sorafenib (Nexavar)
  • Other Therapies

By End User:

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers

By Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website –


Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 24-Oct-2021